Cargando…

Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301

BACKGROUND: The aim of this multicenter, randomized phase II study was to analyze the feasibility and safety of alternate-day S-1, an oral fluoropyrimidine, for adjuvant chemotherapy in patients with completely resected pathological stage I (tumor diameter > 2 cm) non-small cell lung cancer (NSCL...

Descripción completa

Detalles Bibliográficos
Autores principales: Okumura, Norihito, Soh, Junichi, Suzuki, Hiroyuki, Nakata, Masao, Fujiwara, Toshiya, Nakamura, Hiroshige, Sonobe, Makoto, Fujinaga, Takuji, Kataoka, Kazuhiko, Gemba, Kenichi, Kataoka, Masafumi, Hotta, Katsuyuki, Yoshioka, Hiroshige, Matsuo, Keitaro, Sakamoto, Junichi, Date, Hiroshi, Toyooka, Shinichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101150/
https://www.ncbi.nlm.nih.gov/pubmed/33957881
http://dx.doi.org/10.1186/s12885-021-08232-6
_version_ 1783688913634721792
author Okumura, Norihito
Soh, Junichi
Suzuki, Hiroyuki
Nakata, Masao
Fujiwara, Toshiya
Nakamura, Hiroshige
Sonobe, Makoto
Fujinaga, Takuji
Kataoka, Kazuhiko
Gemba, Kenichi
Kataoka, Masafumi
Hotta, Katsuyuki
Yoshioka, Hiroshige
Matsuo, Keitaro
Sakamoto, Junichi
Date, Hiroshi
Toyooka, Shinichi
author_facet Okumura, Norihito
Soh, Junichi
Suzuki, Hiroyuki
Nakata, Masao
Fujiwara, Toshiya
Nakamura, Hiroshige
Sonobe, Makoto
Fujinaga, Takuji
Kataoka, Kazuhiko
Gemba, Kenichi
Kataoka, Masafumi
Hotta, Katsuyuki
Yoshioka, Hiroshige
Matsuo, Keitaro
Sakamoto, Junichi
Date, Hiroshi
Toyooka, Shinichi
author_sort Okumura, Norihito
collection PubMed
description BACKGROUND: The aim of this multicenter, randomized phase II study was to analyze the feasibility and safety of alternate-day S-1, an oral fluoropyrimidine, for adjuvant chemotherapy in patients with completely resected pathological stage I (tumor diameter > 2 cm) non-small cell lung cancer (NSCLC). METHODS: Patients were randomly assigned to receive adjuvant chemotherapy for 1 year comprising either alternate-day oral administration of S-1 (80 mg/m(2)/day) for 4 days a week (Group A) or a 2-week oral administration of S-1 (80 mg/m(2)/day) followed by 1 week of rest (Group B). The primary endpoint was feasibility, which was defined as the proportion of patients who completed the allocated intervention for 6 months with a relative dose intensity (RDI) of 70% or more. RESULTS: Ninety-three patients were enrolled of whom 90 patients received S-1 treatment. Median follow-up was 66.9 months. The treatment completion rate based on an RDI of 70% or more for 6 months was 84.4% (95%CI; 70.5–93.5%) in group A and 64.4% (95%CI; 48.8–78.1%) in group B. There were no grade 4 adverse events in either group. Moderate or severe adverse events (grade 2 or grade 3) were significantly more frequent in group B (67%) compared with group A (29%, P = 0.001). The 5-year relapse-free survival rate was 87.0 and 80.9% for group A and B, respectively (P = 0.451). The 5-year overall survival rate for all patients (n = 93) was 100 and 89.4% for group A and B, respectively (P = 0.136). CONCLUSION: Alternate-day oral administration of S-1 for 1 year as adjuvant chemotherapy was demonstrated to be feasible with low toxicity in completely resected stage I (tumor diameter > 2 cm) NSCLC. TRIAL REGISTRATION: Trial registration number: UMIN000011994. Date of registration: 10/8/2013. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08232-6.
format Online
Article
Text
id pubmed-8101150
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81011502021-05-06 Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301 Okumura, Norihito Soh, Junichi Suzuki, Hiroyuki Nakata, Masao Fujiwara, Toshiya Nakamura, Hiroshige Sonobe, Makoto Fujinaga, Takuji Kataoka, Kazuhiko Gemba, Kenichi Kataoka, Masafumi Hotta, Katsuyuki Yoshioka, Hiroshige Matsuo, Keitaro Sakamoto, Junichi Date, Hiroshi Toyooka, Shinichi BMC Cancer Research Article BACKGROUND: The aim of this multicenter, randomized phase II study was to analyze the feasibility and safety of alternate-day S-1, an oral fluoropyrimidine, for adjuvant chemotherapy in patients with completely resected pathological stage I (tumor diameter > 2 cm) non-small cell lung cancer (NSCLC). METHODS: Patients were randomly assigned to receive adjuvant chemotherapy for 1 year comprising either alternate-day oral administration of S-1 (80 mg/m(2)/day) for 4 days a week (Group A) or a 2-week oral administration of S-1 (80 mg/m(2)/day) followed by 1 week of rest (Group B). The primary endpoint was feasibility, which was defined as the proportion of patients who completed the allocated intervention for 6 months with a relative dose intensity (RDI) of 70% or more. RESULTS: Ninety-three patients were enrolled of whom 90 patients received S-1 treatment. Median follow-up was 66.9 months. The treatment completion rate based on an RDI of 70% or more for 6 months was 84.4% (95%CI; 70.5–93.5%) in group A and 64.4% (95%CI; 48.8–78.1%) in group B. There were no grade 4 adverse events in either group. Moderate or severe adverse events (grade 2 or grade 3) were significantly more frequent in group B (67%) compared with group A (29%, P = 0.001). The 5-year relapse-free survival rate was 87.0 and 80.9% for group A and B, respectively (P = 0.451). The 5-year overall survival rate for all patients (n = 93) was 100 and 89.4% for group A and B, respectively (P = 0.136). CONCLUSION: Alternate-day oral administration of S-1 for 1 year as adjuvant chemotherapy was demonstrated to be feasible with low toxicity in completely resected stage I (tumor diameter > 2 cm) NSCLC. TRIAL REGISTRATION: Trial registration number: UMIN000011994. Date of registration: 10/8/2013. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08232-6. BioMed Central 2021-05-06 /pmc/articles/PMC8101150/ /pubmed/33957881 http://dx.doi.org/10.1186/s12885-021-08232-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Okumura, Norihito
Soh, Junichi
Suzuki, Hiroyuki
Nakata, Masao
Fujiwara, Toshiya
Nakamura, Hiroshige
Sonobe, Makoto
Fujinaga, Takuji
Kataoka, Kazuhiko
Gemba, Kenichi
Kataoka, Masafumi
Hotta, Katsuyuki
Yoshioka, Hiroshige
Matsuo, Keitaro
Sakamoto, Junichi
Date, Hiroshi
Toyooka, Shinichi
Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301
title Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301
title_full Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301
title_fullStr Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301
title_full_unstemmed Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301
title_short Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301
title_sort randomized phase ii study of daily and alternate-day administration of s-1 for adjuvant chemotherapy in completely-resected stage i non-small cell lung cancer: results of the setouchi lung cancer group study 1301
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101150/
https://www.ncbi.nlm.nih.gov/pubmed/33957881
http://dx.doi.org/10.1186/s12885-021-08232-6
work_keys_str_mv AT okumuranorihito randomizedphaseiistudyofdailyandalternatedayadministrationofs1foradjuvantchemotherapyincompletelyresectedstageinonsmallcelllungcancerresultsofthesetouchilungcancergroupstudy1301
AT sohjunichi randomizedphaseiistudyofdailyandalternatedayadministrationofs1foradjuvantchemotherapyincompletelyresectedstageinonsmallcelllungcancerresultsofthesetouchilungcancergroupstudy1301
AT suzukihiroyuki randomizedphaseiistudyofdailyandalternatedayadministrationofs1foradjuvantchemotherapyincompletelyresectedstageinonsmallcelllungcancerresultsofthesetouchilungcancergroupstudy1301
AT nakatamasao randomizedphaseiistudyofdailyandalternatedayadministrationofs1foradjuvantchemotherapyincompletelyresectedstageinonsmallcelllungcancerresultsofthesetouchilungcancergroupstudy1301
AT fujiwaratoshiya randomizedphaseiistudyofdailyandalternatedayadministrationofs1foradjuvantchemotherapyincompletelyresectedstageinonsmallcelllungcancerresultsofthesetouchilungcancergroupstudy1301
AT nakamurahiroshige randomizedphaseiistudyofdailyandalternatedayadministrationofs1foradjuvantchemotherapyincompletelyresectedstageinonsmallcelllungcancerresultsofthesetouchilungcancergroupstudy1301
AT sonobemakoto randomizedphaseiistudyofdailyandalternatedayadministrationofs1foradjuvantchemotherapyincompletelyresectedstageinonsmallcelllungcancerresultsofthesetouchilungcancergroupstudy1301
AT fujinagatakuji randomizedphaseiistudyofdailyandalternatedayadministrationofs1foradjuvantchemotherapyincompletelyresectedstageinonsmallcelllungcancerresultsofthesetouchilungcancergroupstudy1301
AT kataokakazuhiko randomizedphaseiistudyofdailyandalternatedayadministrationofs1foradjuvantchemotherapyincompletelyresectedstageinonsmallcelllungcancerresultsofthesetouchilungcancergroupstudy1301
AT gembakenichi randomizedphaseiistudyofdailyandalternatedayadministrationofs1foradjuvantchemotherapyincompletelyresectedstageinonsmallcelllungcancerresultsofthesetouchilungcancergroupstudy1301
AT kataokamasafumi randomizedphaseiistudyofdailyandalternatedayadministrationofs1foradjuvantchemotherapyincompletelyresectedstageinonsmallcelllungcancerresultsofthesetouchilungcancergroupstudy1301
AT hottakatsuyuki randomizedphaseiistudyofdailyandalternatedayadministrationofs1foradjuvantchemotherapyincompletelyresectedstageinonsmallcelllungcancerresultsofthesetouchilungcancergroupstudy1301
AT yoshiokahiroshige randomizedphaseiistudyofdailyandalternatedayadministrationofs1foradjuvantchemotherapyincompletelyresectedstageinonsmallcelllungcancerresultsofthesetouchilungcancergroupstudy1301
AT matsuokeitaro randomizedphaseiistudyofdailyandalternatedayadministrationofs1foradjuvantchemotherapyincompletelyresectedstageinonsmallcelllungcancerresultsofthesetouchilungcancergroupstudy1301
AT sakamotojunichi randomizedphaseiistudyofdailyandalternatedayadministrationofs1foradjuvantchemotherapyincompletelyresectedstageinonsmallcelllungcancerresultsofthesetouchilungcancergroupstudy1301
AT datehiroshi randomizedphaseiistudyofdailyandalternatedayadministrationofs1foradjuvantchemotherapyincompletelyresectedstageinonsmallcelllungcancerresultsofthesetouchilungcancergroupstudy1301
AT toyookashinichi randomizedphaseiistudyofdailyandalternatedayadministrationofs1foradjuvantchemotherapyincompletelyresectedstageinonsmallcelllungcancerresultsofthesetouchilungcancergroupstudy1301